All In Biotech

Drug Trial Radar · NCT02105948

Study to Evaluate Efficacy and Safety of Mepolizumab for Frequently Exacerbating Chronic Obstructive Pulmonary Disease (COPD) Patients

Study MEA117106: Mepolizumab vs. Placebo as add-on Treatment for Frequently Exacerbating COPD Patients

Last checked: Nov 20, 2026Latest source record: Aug 31, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 837 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

837

Actual

Start

Apr 15, 2014

Primary completion

Jan 17, 2017

Study completion Jan 17, 2017

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Apr 7, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multi-center, randomized, placebo-controlled, double-blind, parallel group trial evaluating mepolizumab 100 mg against placebo given every 4 weeks through subcutaneous (SC) injection. In severe COPD patients, sputum eosinophils levels are elevated similar as those seen in severe asthmatics. It is hypothesized that the reduction of eosinophils with mepolizumab in COPD patients would translate into a reduction of COPD exacerbations. The study will determine the reduction in exacerbations in subjects who are above and below the baseline blood eosinophil count of at least 150 cells/microlitres. The study will evaluate the efficacy and safety of mepolizumab on the frequency of moderate and severe exacerbations in COPD subjects at high risk of exacerbations, despite the use of optimized standard of care background therapy. Overall in this study, a total of 800 subjects will be randomised in 1:1 ratio to receive placebo or mepolizumab (100 milligram (mg)) administered SC. The total duration of this study will be approximately 62 weeks, consisting of a 1 to 2 week screening period, 52-week treatment period and 8-week follow-up period.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • MepolizumabDrug

    Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.

  • PlaceboDrug

    Sterile 0.9% sodium chloride solution

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of Moderate or Severe Exacerbations in Participants in the High StratumTime frame: From randomization to Week 52
  2. Rate of Moderate or Severe Exacerbations in the mITT PopulationTime frame: From randomization to Week 52

Locations

116 sites in 16 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Newport Beach, California

  • GSK Investigational Site

    Rochester, Minnesota

  • GSK Investigational Site

    Saint Charles, Missouri

  • GSK Investigational Site

    New York, New York

  • GSK Investigational Site

    Charlotte, North Carolina

  • GSK Investigational Site

    Durham, North Carolina

  • GSK Investigational Site

    Gastonia, North Carolina

  • GSK Investigational Site

    Huntersville, North Carolina

  • GSK Investigational Site

    Wilmington, North Carolina

  • GSK Investigational Site

    Winston-Salem, North Carolina

  • GSK Investigational Site

    Dayton, Ohio

  • GSK Investigational Site

    Medford, Oregon

  • GSK Investigational Site

    Pittsburgh, Pennsylvania

  • GSK Investigational Site

    Easley, South Carolina

  • GSK Investigational Site

    Fort Mill, South Carolina

  • GSK Investigational Site

    Gaffney, South Carolina

  • GSK Investigational Site

    Greenville, South Carolina

  • GSK Investigational Site

    Seneca, South Carolina

  • GSK Investigational Site

    Spartanburg, South Carolina

  • GSK Investigational Site

    Abingdon, Virginia

  • GSK Investigational Site

    Liverpool, Australia

  • GSK Investigational Site

    Cairns, Queensland, Australia

  • GSK Investigational Site

    Daw Park, South Australia, Australia

  • GSK Investigational Site

    Clayton, Victoria, Australia

  • GSK Investigational Site

    Frankston, Victoria, Australia

  • GSK Investigational Site

    Murdoch, Western Australia, Australia

  • GSK Investigational Site

    Nedlands, Western Australia, Australia

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Brussels, Belgium

  • GSK Investigational Site

    Erpent, Belgium

  • GSK Investigational Site

    Leuven, Belgium

  • GSK Investigational Site

    Liège, Belgium

  • GSK Investigational Site

    Ostend, Belgium

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Sherwood Park, Alberta, Canada

  • GSK Investigational Site

    Winnipeg, Manitoba, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Windsor, Ontario, Canada

  • GSK Investigational Site

    Gatineau, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

Showing 40 of 116 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.